Comparison Korean National Health Insurance Reimbursement and Other Guidelines for TNF-alpha Blocker in Rheumatoid Arthritis.
10.4078/jrd.2012.19.6.334
- Author:
Kyeong Min SON
1
;
Dong Min JUNG
;
Yul Bin KIM
;
Ji Suk HAN
;
Young Il SEO
;
Young Ok JUNG
;
In Je KIM
;
Hyun Ah KIM
Author Information
1. Division of Rheumatology, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea. kimha@hallym.ac.kr
- Publication Type:Original Article
- Keywords:
Korean National Health Insurance reimbursement criteria;
Rheumatoid arthritis;
TNF-alpha blocker
- MeSH:
Arthritis, Rheumatoid;
Humans;
Isoxazoles;
Japan;
Joints;
Methotrexate;
National Health Programs;
Rheumatology;
Tumor Necrosis Factor-alpha
- From:Journal of Rheumatic Diseases
2012;19(6):334-340
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The aim of this study was to examine how many Korean rheumatoid arthritis (RA) patients fulfilling the 2008 American College of Rheumatology (ACR) recommendation, 2007 British Society for Rheumatology (BSR) guideline and 2010 Japan College of Rheumatology (JCR) guideline for TNF-alpha blocker, meet the Korean National Health Insurance reimbursement criteria and to evaluate the reasons for failing the Korean National Health Insurance reimbursement criteria. METHODS: Data were obtained from a registry of RA patients who visited rheumatology clinics of Hallym university affiliated hospitals. Patients who were previously prescribed with methotrexate or leflunomide for more than 3 months and had at least one DAS28 examination were included in the present study. RESULTS: Of 642 patients included, 118 episodes meeting ACR guideline for using TNF-alpha blocker were identified in 88 patients (13.7%). In addition, 19 episodes meeting BSR guideline in 17 patients (2.6%) and 21 episodes meeting JCR guideline in 21 patients (6.2%) were identified. Four episodes (4.8%) meeting ACR recommendation, 0 episodes meeting BSR criteria and 5 episodes (12%) meeting JCR criteria, respectively, were eligible for TNF-alpha blocker according to the Korean National Health Insurance reimbursement guideline. The most common reason for failing the Korean National Health Insurance reimbursement criteria was the number of active joint counts (92.6%). CONCLUSION: Our results show that the majority of RA patients satisfying the ACR guideline, BSR and JCR guideline for use of the TNF-alpha blocker did not meet the Korean National Health Insurance reimbursement criteria. Patients most often failed due to active joint count criteria.
